halofusol 0,5 mg/ml oral lösning
laboratorios karizoo s.a. - halofuginonlaktat - oral lösning - 0,5 mg/ml - bensoesyra hjälpämne; halofuginonlaktat 0,609 mg aktiv substans; tartrazin hjälpämne - nöt
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
isoflutek vet 1000 mg/g inhalationsånga, vätska
laboratorios karizoo s.a. - isofluran - inhalationsånga, vätska - 1000 mg/g - isofluran 1000 mg aktiv substans - burfåglar, chinchilla, hamster, hund, häst, iller, katt, marsvin, mus, reptiler, råtta
suiseng diff/a
laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - grisar - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.
azacitidine lorien 25 mg/ml pulver till injektionsvätska, suspension
laboratorios lorien s.l. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne
porcivac ery parvo injektionsvätska, emulsion
laboratorios syva s.a. - erysipelothrix rhusiopathiae, serotyp 2, stam se-9, inaktiverad; porcint parvovirus, stam pvp-7, inaktiverat - injektionsvätska, emulsion - montanide isa 201 vg 0,91 g adjuvans; tiomersal hjälpämne; porcint parvovirus, stam pvp-7, inaktiverat 320 - 5120 hit aktiv substans; erysipelothrix rhusiopathiae, serotyp 2, stam se-9, inaktiverad 7,4 - 61 elisa e aktiv substans - svin
fentanyl basi 50 mikrogram/ml injektionsvätska, lösning
laboratorios basi - industria farmaceutica s.a. - fentanylcitrat - injektionsvätska, lösning - 50 mikrogram/ml - fentanylcitrat 78,5 mikrog aktiv substans
cristalmina 10 mg/ml kutan spray, lösning
laboratorios salvat s.a. - klorhexidindiglukonat - kutan spray, lösning - 10 mg/ml - klorhexidindiglukonat 10 mg aktiv substans
ketorolac s.a.l.f. 30 mg/ml injektionsvätska, lösning
s.a.l.f. spa laboratorio farmacologico - ketorolaktrometamol - injektionsvätska, lösning - 30 mg/ml - etanol, vattenfri hjälpämne; ketorolaktrometamol 30 mg aktiv substans
labetalol s.a.l.f. 5 mg/ml injektions-/infusionsvätska, lösning
s.a.l.f. spa laboratorio farmacologico - labetalolhydroklorid - injektions-/infusionsvätska, lösning - 5 mg/ml - glukosmonohydrat hjälpämne; labetalolhydroklorid 5 mg aktiv substans